Talptera, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Talptera, Inc. (TLPH) has filed its 2023 10-K report, detailing financial performance and corporate events, including significant warrant activity.</b>

AI Summary

TALPHERA, INC. (TLPH) filed a Annual Report (10-K) with the SEC on March 6, 2024. Talptera, Inc. (formerly Acelrx Pharmaceuticals Inc.) filed its annual report for the fiscal year ending December 31, 2023. The company's business address is 1850 Gateway Drive, Suite 175, San Mateo, CA 94404. The filing indicates various warrant issuances and amendments throughout 2023 and early 2024. Key subsequent events include warrant amendments and private placements in January 2024. The report covers financial activities and corporate actions for the fiscal year 2023.

Why It Matters

For investors and stakeholders tracking TALPHERA, INC., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Talptera's financial health and operational status for the fiscal year 2023, crucial for investors assessing the company's trajectory. The numerous warrant-related events mentioned, particularly in early 2024, suggest potential future dilution or capital raising activities that could impact shareholder value.

Risk Assessment

Risk Level: medium — TALPHERA, INC. shows moderate risk based on this filing. The company's financial disclosures are limited in this extract, making a full assessment of its financial health difficult. However, the mention of various warrant activities suggests potential future dilution or capital structure changes.

Analyst Insight

Investors should closely examine the detailed financial statements and the 'Risk Factors' section within the full 10-K filing to understand the implications of the company's warrant activities and overall financial position.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting period)
• 2024-03-06 — Filing Date (Date of submission)
• 2834 — SIC Code (Pharmaceutical Preparations)
• 001-35068 — SEC File Number (SEC registration number)

Key Players & Entities

• TALPHERA, INC. (company) — Filer name
• ACELRX PHARMACEUTICALS INC (company) — Former company name
• 2023-12-31 (date) — Fiscal year end
• 2024-03-06 (date) — Filing date
• 1850 Gateway Drive, Suite 175, San Mateo, CA 94404 (address) — Business address
• TLPH (ticker) — Ticker symbol

FAQ

Risk Factors

• Warrant Activity [medium — financial]: The company engaged in multiple warrant issuances and amendments throughout 2023 and early 2024, including subsequent events related to private placements and milestone-based warrants.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K.
• 2024-01-17: Subsequent Event - Warrant Activity — Indicates significant warrant-related transactions occurring after the fiscal year-end.
• 2024-01-12: Subsequent Event - XOMA Agreement — Refers to an agreement related to XOMA, occurring after the fiscal year-end.

Key Financial Figures

• $0.001 — nge on Which Registered Common Stock, $0.001 par value TLPH The Nasdaq Global Ma
• $32.5 million — tion for consideration of approximately $32.5 million plus net cash acquired and certain othe
• $26.0 million — and which includes up to approximately $26.0 million of contingent consideration payable in
• $200 million — Niyad's peak sales potential may exceed $200 million annually in the United States if it is
• $575 m — of 500,000 patients undergoing CRRT of $575 million, and an estimated addressable pop
• $3.5 billion — n of 350,000 patients undergoing IHD of $3.5 billion. Exposure of blood to the

Filing Documents

• acrx20231231_10k.htm (10-K) — 2255KB
• ex_630372.htm (EX-23.1) — 2KB
• ex_634781.htm (EX-23.2) — 3KB
• ex_630371.htm (EX-31.1) — 8KB
• ex_630370.htm (EX-31.2) — 8KB
• ex_630369.htm (EX-32.1) — 6KB
• ex_634782.htm (EX-97) — 33KB
• 0001437749-24-006849.txt (&nbsp;) — 11015KB
• tlph-20231231.xsd (EX-101.SCH) — 98KB
• tlph-20231231_def.xml (EX-101.DEF) — 675KB
• tlph-20231231_lab.xml (EX-101.LAB) — 593KB
• tlph-20231231_pre.xml (EX-101.PRE) — 710KB
• tlph-20231231_cal.xml (EX-101.CAL) — 81KB
• acrx20231231_10k_htm.xml (XML) — 1808KB

Risk Factors

Item 1A. Risk Factors 21

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments 46

Cybersecurity

Item 1C. Cybersecurity 46

Properties

Item 2. Properties 47

Legal Proceedings

Item 3. Legal Proceedings 47

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 47 PART II 48

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 48

Reserved

Item 6. Reserved 48

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 49

Quantitative and Qualitative Disclosures about Market Risk

Item 7A. Quantitative and Qualitative Disclosures about Market Risk 60

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data 60

Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 60

Controls and Procedures

Item 9A. Controls and Procedures 61

Other Information

Item 9B. Other Information 62

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. 62 PART III 62

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 62

Executive Compensation

Item 11. Executive Compensation 62

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 62

Certain Relationships and Related Transactions and Director Independence

Item 13. Certain Relationships and Related Transactions and Director Independence 62

Principal Accounting Fees and Services

Item 14. Principal Accounting Fees and Services 62 PART IV 63

Exhibits and Financial Statement Schedules

Item 15. Exhibits and Financial Statement Schedules 63

Form 10-K Summary

Item 16. Form 10-K Summary 66

SIGNATURES

SIGNATURES 67 6 PART I

Business

Item 1. Business Overview We are a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Our Portfolio Our portfolio consists of nafamostat product candidates and pre-filled syringe product candidates, as further described below. In January 2022, we acquired Lowell Therapeutics, Inc., or Lowell, a privately held company, pursuant to the Agreement and Plan of Merger, dated as of November 14, 2021, or the Merger Agreement, in a transaction for consideration of approximately $32.5 million plus net cash acquired and certain other adjustments, and which includes up to approximately $26.0 million of contingent consideration payable in cash or stock at our option, upon the achievement of regulatory and sales-based milestones, or the Merger Agreement. In connection with the Merger Agreement we acquired Niyad and LTX-608 (lyophilized vials of nafamostat for injection into the extracorporeal circuit or direct IV infusion to the patient, respectively), an in-process research and development, or IPR&D, asset. For additional information regarding the Merger Agreement, see Note 4, "Asset Acquisition" to the consolidated financial statements in this Annual Report on Form 10-K for additional information. 7 Nafamostat Product Candidates Product/Product Candidate Description Target Use Status Niyad Lyophilized vial containing nafamostat for injection Regional anticoagulant for injection into the extracorporeal circuit Received an investigational device exemption, or IDE, and Breakthrough Device Designation from the United States Food and Drug Administration, or FDA. Plan to begin enrollment in a registrational trial in the first quarter of 2024 and submit a Premarket Approval, or PMA, application to the FDA by the end of 2024. LTX-608 Lyophilized vial containing nafamostat for injection IV infusion for disseminated intravascular coagulation, or DIC, acute respirat

View Full Filing

View this 10-K filing on SEC EDGAR